Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies

Arnon P. Kater, Sanne H. Tonino, Marjolein Spiering, Martine E. D. Chamuleau, Roberto Liu, Adeboye Henry Adewoye, Jie Gao, Lyndah Dreiling, Yan Xin, Jeanette K. Doorduijn, Marie José Kersten

Research output: Contribution to journalComment/Letter to the editorAcademic

Cite this